Cargando…
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF
BACKGROUND: The standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and platin-fluoropyrimidine chemotherapy. As some patients do not respond to trastuzumab therapy or develop resistance during treatment, the search for alternative...
Autores principales: | Ebert, Karolin, Haffner, Ivonne, Zwingenberger, Gwen, Keller, Simone, Raimúndez, Elba, Geffers, Robert, Wirtz, Ralph, Barbaria, Elena, Hollerieth, Vanessa, Arnold, Rouven, Walch, Axel, Hasenauer, Jan, Maier, Dieter, Lordick, Florian, Luber, Birgit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908634/ https://www.ncbi.nlm.nih.gov/pubmed/35264144 http://dx.doi.org/10.1186/s12885-022-09335-4 |
Ejemplares similares
-
Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
por: Ebert, Karolin, et al.
Publicado: (2020) -
Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
por: Ebert, Karolin, et al.
Publicado: (2020) -
Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines
por: Raimúndez, Elba, et al.
Publicado: (2020) -
Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer
por: Kunzke, Thomas, et al.
Publicado: (2021) -
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018)